NCT01795313 2026-02-05
Immunotherapy for Recurrent Ependymomas in Children Using Tumor Antigen Peptides With Imiquimod
University of Pittsburgh
Phase 1 Terminated
Clinical Trials
14 trialsNCT04809662 2024-11-07
Comparing Immune Responses to Topical Imiquimod
University of California, Davis
Terminated
NCT03982004 2021-06-21
Epicutaneous Cryoimmunotherapy Combined With Pembrolizumab for Cutaneous Metastatic Breast Cancer
Washington University School of Medicine
Phase 1 Terminated
NCT02224599 2020-04-24
Cyclophosphamide, TAPA-Pulsed Dendritic Cell Therapy and Imiquimod in Progressive and/or Refractory Solid Malignancies
Kiromic BioPharma Inc.
Phase 1/2 Terminated
NCT01400672 2020-03-18
Imiquimod/Brain Tumor Initiating Cell (BTIC) Vaccine in Brain Stem Glioma
Masonic Cancer Center, University of Minnesota
Phase 1 Terminated
NCT01191034 2019-03-12
Peptide Vaccination Associated With Tumoral Immunomodulation in Patients With Advanced Metastatic Melanoma
Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Phase 1/2 Terminated
NCT02329171 2018-08-15
TOPIC
Maastricht University Medical Center
Phase 3 Terminated
NCT00979550 2018-03-22
The Effects of Aldara as an Adjunct to Laser Treatment
University of Kentucky
Phase 2 Terminated
NCT01538901 2017-09-12
AKtransplant
Medical University of Vienna
Phase 4 Terminated
NCT01902771 2017-03-10
Dendritic Cell Vaccine Therapy With In Situ Maturation in Pediatric Brain Tumors
University of Miami
Phase 1 Terminated
NCT02689726 2016-12-02
Safety, Tolerability, and Immunogenicity of GTL001 Vaccine Adjuvanted With Imiquimod Cream in HPV 16- and/or HPV 18-Infected Women Aged 25 to 65 Years, With Normal Cytology, ASCUS, or LSIL
Genticel
Phase 1 Terminated
NCT01283763 2016-11-01
ITIC2
Medical University of Vienna
Phase 3 Terminated
NCT01203878 2014-12-08
Treatment of Actinic Keratoses of the Face With Imiquimod 3.75% Cream Followed by Photodynamic Therapy
Tennessee Clinical Research Center
Phase 4 Terminated
NCT01403285 2014-05-19
Peptide-based Glioma Vaccine IMA950 in Patients With Glioblastoma
Immatics Biotechnologies GmbH
Phase 1 Terminated